Correction: NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer (Breast Cancer Research (2019) 21 (133) DOI: 10.1186/s13058-019-1196-y)
- Jacobs, S.A.
- Robidoux, A.
- Abraham, J.
- Pérez-Garcia, J.M.
- La Verde, N.
- Orcutt, J.M.
- Cazzaniga, M.E.
- Piette, F.
- Antolín, S.
- Aguirre, E.
- Cortes, J.
- Llombart-Cussac, A.
- Di Cosimo, S.
- Kim, R.S.
- Feng, H.
- Lipchik, C.
- Lucas, P.C.
- Srinivasan, A.
- Wang, Y.
- Song, N.
- Gavin, P.G.
- Balousek, A.D.
- Paik, S.
- Allegra, C.J.
- Wolmark, N.
- Pogue-Geile, K.L.
- Montrer des auteurs +
ISSN: 1465-542X, 1465-5411
Année de publication: 2020
Volumen: 22
Número: 1
Type: Erreur